Stuart C Apfel

US Patent:

54201128, May 30, 1995

Filed:

Apr 16, 1993

Appl. No.:

8/051191

Inventors:

Michael E. Lewis - West Chester PA
Stuart C. Apfel - West Hempstead NY
John A. Kessler - New Canaan CT

International Classification:

A61K 3800
A61K 3804
A61K 3808
A61K 3822

US Classification:

514 12

Abstract:

The invention features a method of preventing or treating a peripheral neuropathy that results from a systemic disease (e. g. , post-polio syndrome) or a toxic agent (e. g. , a chemotherapeutic agent), and that is not caused by an abnormal insulin level in a mammal. The method involves administering a neuropathy-reducing amount of insulin-like growth factor-I (IGF-I) or insulin-like growth factor-III (IGF-III) to the mammal.

US Patent:

56042027, Feb 18, 1997

Filed:

Nov 17, 1993

Appl. No.:

8/153796

Inventors:

John A. Kessler - New Canaan CT
Stuart C. Apfel - West Hempstead NY

Assignee:

Albert Einstein College of Medicine of Yeshiva University, a Division of
Yeshiva University

International Classification:

A61K 3800
A61K 5100

US Classification:

514 12

Abstract:

This invention relates to the use of neuronotrophic factors, such as nerve growth factor (NGF), ciliary derived neuronotrophic factor (CNTF), brain derived neuronotrophic factor (BDNF), neuronotrophin-3 (NT-3), fibroblast growth factor (FGF), epidermal growth factor (EGF), transforming growth factor. varies. (TFG-. varies. ), transforming growth factor. beta. (TGF-. beta. ) and others to prevent drug-induced neuropathy.

US Patent:

55853480, Dec 17, 1996

Filed:

Aug 13, 1993

Appl. No.:

8/106401

Inventors:

Stanley M. Crain - Leonia NJ
Ke-fei Shen - Flushing NY
John A. Kessler - New Canaan CT
Stuart C. Apfel - West Hempstead NY

Assignee:

Albert Einstein College of Medicine of Yeshiva University, a Division of
Yeshiva University - Bronx NY

International Classification:

A61K 3800

US Classification:

514 12

Abstract:

This invention relates to a method of preventing hyperalgesia and other undesirable side-effects associated with the administration of growth factor, including nerve growth factor, utilizing an antagonist capable of inactivating excitatory opioid receptor-mediated functions on neurons in the nociceptive pathway. In addition, this invention relates to a composition comprising a growth factor and an antagonist capable of inactivating excitatory opioid receptor-mediated functions on neurons in the nociceptive pathway.

US Patent:

56483350, Jul 15, 1997

Filed:

Jun 4, 1996

Appl. No.:

8/658198

Inventors:

Michael E. Lewis - West Chester PA
Stuart C. Apfel - West Hempstead NY
John A. Kessler - New Canaan CT

Assignee:

Cephalon, Inc. - West Chester PA
Albert Einstein College of Medicine of Yeshiva Univ. - Bronx NY

International Classification:

A61K 3800
A61K 3804
A61K 3808
A61K 3802

US Classification:

514 12

Abstract:

The invention features a method of using insulin-like growth factor-I (IGF-I) or insulin-like growth factor-III (IGF-III) to prevent or treat peripheral neuropathy in a mammal.

US Patent:

55696481, Oct 29, 1996

Filed:

Dec 29, 1994

Appl. No.:

8/365796

Inventors:

Michael E. Lewis - West Chester PA
Stuart C. Apfel - West Hempstead NY
John A. Kessler - New Canaan CT

Assignee:

Cephalon, Inc. - West Chester PA
Albert Einstein College of Medicine of Yeshiva University - Bronx NY

International Classification:

A61K 3800
A61K 3804
A61K 3808
A61K 3822

US Classification:

514 12

Abstract:

The invention features a method of using insulin-like growth factor-I (IGF-I) or insulin-like growth factor-III (IGF-III) to prevent or treat peripheral neuropathy in a mammal.

US Patent:

56332289, May 27, 1997

Filed:

Dec 29, 1994

Appl. No.:

8/366049

Inventors:

Michael E. Lewis - West Chester PA
Stuart C. Apfel - West Hempstead NY
John A. Kessler - New Canaan CT

Assignee:

Cephalon, Inc., - West Chester PA
Albert Einstein College of Medicine of Yeshiva University - Bronx NY

International Classification:

A61K 3800
A61K 3827

US Classification:

514 12

Abstract:

The invention features a method of using insulin-like growth factor-I (IGF-I) or insulin-like growth factor-III (IGF-III) to prevent or treat peripheral neuropathy in a mammal.

US Patent:

6011004, Jan 4, 2000

Filed:

Dec 17, 1996

Appl. No.:

8/768221

Inventors:

John A. Kessler - New Canaan CT
Stuart C. Apfel - West Hempstead NY

Assignee:

Albert Einstein College of Medicine of Yeshiva University - Bronx NY

International Classification:

A61K 3818

US Classification:

514 2

Abstract:

This invention relates to the use of neuronotrophic factors, such as nerve growth factor (NGF), ciliary derived neuronotrophic factor (CNTF), brain derived neuronotrophic factor (BDNF), neuronotrophin-3 (NT-3), fibroblast growth factor (FGF), epidermal growth factor (EGF), transforming growth factor. alpha. (TFG-. alpha. ), transforming growth factor. beta. (TGF-. beta. ) and others to prevent drug-induced neuropathy.